AbbVie Inc (ABBV) : Annex Advisory Services reduced its stake in AbbVie Inc by 1.31% during the most recent quarter end. The investment management company now holds a total of 24,278 shares of AbbVie Inc which is valued at $1,631,239 after selling 322 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.AbbVie Inc makes up approximately 0.43% of Annex Advisory Services’s portfolio.
Other Hedge Funds, Including , Foster Dykema Cabot Co Incma reduced its stake in ABBV by selling 680 shares or 8.28% in the most recent quarter. The Hedge Fund company now holds 7,532 shares of ABBV which is valued at $506,075. AbbVie Inc makes up approx 0.11% of Foster Dykema Cabot Co Incma’s portfolio.Cetera Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 6,200 additional shares and now holds a total of 51,269 shares of AbbVie Inc which is valued at $3,444,764. AbbVie Inc makes up approx 0.26% of Cetera Advisors’s portfolio.Halbert Hargroverussell boosted its stake in ABBV in the latest quarter, The investment management firm added 113 additional shares and now holds a total of 3,713 shares of AbbVie Inc which is valued at $248,585. AbbVie Inc makes up approx 0.07% of Halbert Hargroverussell’s portfolio.Perkins Capital Management Inc reduced its stake in ABBV by selling 1,000 shares or 5.41% in the most recent quarter. The Hedge Fund company now holds 17,475 shares of ABBV which is valued at $1,115,080. AbbVie Inc makes up approx 1.23% of Perkins Capital Management Inc’s portfolio.Hartford Investment Management Co reduced its stake in ABBV by selling 9,851 shares or 2.4% in the most recent quarter. The Hedge Fund company now holds 401,264 shares of ABBV which is valued at $25,604,656. AbbVie Inc makes up approx 0.52% of Hartford Investment Management Co’s portfolio.
AbbVie Inc closed down -0.84 points or -1.25% at $66.17 with 1,02,27,754 shares getting traded on Tuesday. Post opening the session at $67.26, the shares hit an intraday low of $65.99 and an intraday high of $67.49 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.